Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04089371 · ClinicalTrials.gov registry record
A Post-Market Clinical Evaluation of the ReUnion Reversible Fracture (RFX) System
A clinical trial, sponsored by Stryker Trauma and Extremities.
- Terminated
- Registry status
- 10
- Enrollment target
NCT04089371 is a clinical trial that was terminated before completion, run by Stryker Trauma and Extremities. The registered enrollment target is 10 participants.
The verdict
NCT04089371 was terminated before completion, sponsored by Stryker Trauma and Extremities.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
This investigation is a prospective, multi-center clinical investigation. It is anticipated that a total of one hundred (100) subjects will be enrolled at approximately 5-10 sites. The clinical investigation has been designed to follow the surgeon's standard of care for joint arthroplasty patients, which entails clinical evaluation on a regular ongoing basis, or as needed should the patient become symptomatic in the treated joint.
Interventions
- DEVICE ReUnion Total Shoulder Arthroplasty (TSA)
- DEVICE ReUnion Reverse Shoulder Arthroplasty (RSA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2022-07-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04089371
The ClinicalTrials.gov registry entry for NCT04089371 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stryker Trauma and Extremities, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ReUnion Total Shoulder Arthroplasty (TSA) is the first listed.
NCT04089371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04089371 about?
NCT04089371 is a clinical study titled "A Post-Market Clinical Evaluation of the ReUnion Reversible Fracture (RFX) System". This investigation is a prospective, multi-center clinical investigation. It is anticipated that a total of one hundred (100) subjects will be enrolled at approximately 5-10 sites. The clinical investigation has been designed to follow the surgeon's standard of care for joint arthroplasty patients, ...
What is the current status of trial NCT04089371?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2019-10-01. Estimated completion is 2022-07-08.
What interventions are being tested in trial NCT04089371?
The interventions under investigation include: ReUnion Total Shoulder Arthroplasty (TSA) (DEVICE), ReUnion Reverse Shoulder Arthroplasty (RSA) (DEVICE).
Who is sponsoring clinical trial NCT04089371?
This trial is sponsored by Stryker Trauma and Extremities, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.